Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GINAKIT Cells With or Without Etanercept for Children With Neuroblastoma
NCT03294954Phase 1Active, not recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Jan 2018
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of GINAKIT Cells in neuroblastoma (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Maximum tolerated dose and safety profile at 28 days. Started Jan 2018; status: active, not recruiting.
02
Drugs
GINAKIT Cells
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03294954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03294954.